Benzinga | Apr 19, 2021 10:52AM EDT

Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $125

Morgan Stanley maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $121 to $125.